miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2

Bao, Jie; Xu, Yun; Wang, Qunying; Zhang, Jinping; Li, Zhenjie; Li, Dongying; Li, Jiansheng

doi:10.1016/j.biopha.2017.06.011

Cited by 43 publications

(32 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was found that glioma patients with low ANXA2 and ANXA2 pseudogenes expression could benefit more from chemotherapy and radiotherapy. Summarizing other studies, ANXA2 was upregulated in gastric cancer tissues and as a direct target of miR-101, miR-101 alleviated chemoresistance of cisplatin or vincristine in gastric cancer cells by targeting ANXA2 [ 33 ]. The protein ANXA2 could be bind to a well-known multidrug-efflux transporte named P-gp, which promoted the invasiveness of multidrug-resistant breast cancer cells through regulation of ANXA2 phosphorylation [ 34 ].…”

Section: Discussionmentioning

confidence: 86%

Pseudogenes of annexin A2, novel prognosis biomarkers for diffuse gliomas

Zou

Shao

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Diffuse gliomas is a kind of common malignant primary brain tumor. Pseudogenes have multilayered biological function in the progression of human cancers. In this study, Differentially Expressed Pseudogenes (DEPs) between glioblastomas and non-tumor controls were found by bioinformatics analysis, of which the annexin A2 pseudogenes (ANXA2P1, ANXA2P2 and ANXA2P3) were significantly up-regulated, along with the parent gene annexin A2 (ANXA2). Among four glioblastoma subtypes, ANXA2P1 and ANXA2P2 were preferentially expressed in mesenchymal subtype and less expressed in proneural subtype. Meanwhile, Pearson’s correlation analysis revealed that the expression level of ANXA2 was positively correlated with ANXA2 pseudogenes expression. Then, the expression patterns of ANXA2 and its pseudogenes were validated in diffuse glioma specimens (n=99) and non-tumor tissues (n=12) by quantitative real-time PCR (qRT-PCR). Additionally, Kaplan–Meier analysis revealed that highly expressed ANXA2 and annexin A2 pseudogenes were associated with the poor survival outcome of glioma patients. Cox regression analyses suggested that ANXA2, ANXA2P1 and ANXA2P2 were the independent prognosis factors for gliomas. Furthermore, down-regulation of ANXA2 and ANXA2 pseudogenes might contribute to the improvement of patients’ survival who received chemotherapy and radiotherapy. These results demonstrated that ANXA2 pseudogenes and ANXA2 could be used as the novel biomarkers for diagnosis, prognosis and target therapy of gliomas.

show abstract

Section: Discussionmentioning

confidence: 86%

Pseudogenes of annexin A2, novel prognosis biomarkers for diffuse gliomas

Zou

Shao

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Annexin A2 is proved to be implicated in various cancers, including HCC. 17,[35][36][37][38] For example, Zhang et al reported that shRNA-mediated silencing of ANXA2 suppresses the invasion, migration and tumourigenic potential of hepatoma cells and may thus be utilized as a target of future molecular therapies. 39 As ANXA2 binds with LUCAT1, and considering the desperate need to find a better therapeutic target for HCC patients, we designed subsequent experiments to determine the mechanism of ANXA2 and LUCAT1.…”

Section: Discussion and Con Clusionmentioning

confidence: 99%

Long non‐coding RNA LUCAT1 promotes tumourigenesis by inhibiting ANXA2 phosphorylation in hepatocellular carcinoma

Lou

Yu²,

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

Long non‐coding RNAs (lncRNAs) play essential roles in diverse biological processes; however, current understanding of the mechanism underlying the regulation of tumour proliferation and metastasis is limited. Lung cancer‐associated transcript 1 (LUCAT1) has been reported in a variety of human cancers, while its role in hepatocellular carcinoma (HCC) remains unclear. This study aimed to determine the biological role and underlying mechanism of LUCAT1 on progression and metastasis in HCC cells and clinical specimens. Our results demonstrated that LUCAT1 was up‐regulated in HCC tissues and cells. Loss‐ and gain‐of‐function studies revealed that LUCAT1 promotes the proliferation and metastasis of HCC cells in vitro and in vivo. Furthermore, RNA pulldown and Western blot assays indicated that LUCAT1 inhibited the phosphorylation of Annexin A2 (ANXA2) to reduce the degradation of ANXA2‐S100A10 heterotetramer (AIIt), which in turn accelerated the secretion of plasminogen into plasmin, thereby resulting in the activation of metalloprotease proteins. In conclusion, we propose that LUCAT1 serves as a novel diagnostic and therapeutic target for HCC.

show abstract

“…Recently, several studies showed that miR-101 is widely expressed in various tissues and organs and is frequently downregulated in various cancers [ 34 – 36 ]. miR-101 has been confirmed as a tumor suppressor that can inhibit many critical oncogenes [ 37 , 38 ].…”

Section: Discussionmentioning

confidence: 99%

Low Serum Levels of miR-101 Are Associated with Poor Prognosis of Colorectal Cancer Patients After Curative Resection

He¹,

Yue²,

Li³

et al. 2018

Med Sci Monit

View full text Add to dashboard Cite

BackgroundRecent studies showed low expression of microRNA (miR)-101 in various malignancies. However, the association of serum miR-101 and colorectal cancer (CRC) remains unknown. We investigated diagnostic and prognostic significance of serum miR-101 in CRC.Material/MethodsA total of 263 consecutive CRC patients and 126 healthy controls were enrolled in this study. Serum miR-101 levels were measured using real-time quantitative reverse transcription polymerase chain reactions. The association between serum miR-101 level and survival outcome was analyzed.ResultsSerum miR-101 in CRC patients was significantly lower than in healthy volunteers (P<0.001). Low serum miR-101 level was significantly associated with advanced cancer stage. Moreover, survival analysis demonstrated that patients with a low serum miR-101 had poorer 5-year overall survival than patients with a high serum miR-101 level (p=0.041). Serum miR-101 level also were confirmed as an independent risk factor for CRC in multivariate analysis (hazard ratio, 1.468; 95%CI, 0.981–1.976; p<0.001).ConclusionsSerum miR-101 level was significantly downregulated in CRC patients and was closely correlated with poor clinical outcome, suggesting that serum miR-101 might be a useful diagnostic and prognostic marker for CRC.

show abstract

miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2

Cited by 43 publications

References 31 publications

Pseudogenes of annexin A2, novel prognosis biomarkers for diffuse gliomas

Pseudogenes of annexin A2, novel prognosis biomarkers for diffuse gliomas

Long non‐coding RNA LUCAT1 promotes tumourigenesis by inhibiting ANXA2 phosphorylation in hepatocellular carcinoma

Low Serum Levels of miR-101 Are Associated with Poor Prognosis of Colorectal Cancer Patients After Curative Resection

Contact Info

Product

Resources

About